Cipla signs distribution agreement with Serum Institute of India

Published: 5-Dec-2014
Manufacturing Pharmaceutical

Enters the market for paediatric vaccines in Europe


Cipla Europe, a wholly owned subsidiary of Indian pharmaceutical company Cipla, has signed a distribution agreement with Serum Institute of India (SII), a developer of vaccines.

Under the agreement, SII will develop and manufacture paediatric vaccines while Cipla will seek European Medicines Agency approval and market the products in Europe.

The vaccines will be manufactured in Serum's production facilities approved by the World Health Organization (WHO).

'We are proud to have entered into a strategic Europe-specific partnership with Serum Institute of India,' said Subhanu Saxena, MD and Global CEO, Cipla Limited. 'This collaboration is aligned with our commitment to provide access to affordable paediatric healthcare. Both Cipla and SII share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contributing to the eradication of childhood diseases.'

Frank Pieters, Head of Cipla Europe, added: 'We are focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe.

'We see vaccines as one of the critical components of our offering to European patients. With Cipla's front-end presence and with the support of a dedicated sales force, we will broaden the reach of vaccines across Europe.'

Over the past six months Cipla has been strengthening its foundation in Europe with the launch of respiratory products such as Salmeterol/Fluticasone in Germany and Sweden, Czech Republic, Slovakia and Croatia.

In July, Cipla the company signed an exclusive partnership with BioQuiddity to market OneDoseReadyfusOR in regional anaesthetic applications for post-surgical pain management.

  • Companies:
  • Cipla
  • Serum Institute of India
See more

You may also like

Finance

Cipla to acquire two US generics companies for $550m

Read more
Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Cipla to acquire two US generics companies for $550m

Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Manufacturing

Genticel licenses Vaxiclase platform to Serum Institute of India for use in whooping cough vaccines

Agreement entitles Genticel to up to US$57m in upfront and milestones payments
Finance

2014 Sunday Times Rich List sees entry of more pharma executives

Ernesto and Kirsty Bertarelli are still out ahead of the rest
Pharmaceutical

Cipla aims for export growth

Looking to increase its exports from current 55% to more than 70% of turnover
Research & Development

Serum Institute of India acquires rights to TB vaccine

Researchers continue to refine classic BCG tuberculosis vaccine
Ingredients

Indian API market on the up as domestic drug prices fall

Indian API manufacturers are branching out into new markets, while international suppliers could be hit by lower prices in the domestic market, writes Asia correspondent A Nair
Research & Development

Meda expands collaboration with Cipla

Expands its exclusive rights to allergic rhinitis treatment Dymista
Subscribe now